Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis

Gil Yosipovitch, Marjolein de Bruin-Weller, April Armstrong, Jashin J. Wu, Pedro Herranz, Diamant Thaçi, Dimittri Delevry, Gaëlle Bégo Le Bagousse, Raymond Zhang, Brad Shumel, Ana B. Rossi, Jingdong Chao

Research output: Contribution to journalArticlepeer-review


Introduction: Atopic dermatitis (AD) can have a profound negative impact on the quality of life (QoL) of patients. We analyzed the long-term changes in AD symptoms, QoL, and patient assessment of treatment effect in adults with moderate-to-severe AD treated for 2 years with dupilumab. Methods: LIBERTY AD OLE (NCT01949311) is a multicenter, open-label extension (OLE) study in adults with moderate-to-severe AD who previously participated in dupilumab clinical trials (parent studies). Patients received dupilumab 300 mg weekly. Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), EQ-5D-3L, and the Patient Global Assessment of Treatment Effect (PGATE) were assessed at weeks 48 and 100. Results: A total of 2677 patients were included in the OLE, and 1028 completed week 100. By weeks 48 and 100, 94.1% and 95.6% of patients achieved a ≥ 4-point change in POEM from the parent study baseline (PSBL), respectively, and 93.3% and 93.4% of patients had achieved a ≥ 4-point change in DLQI from PSBL, respectively. At week 100, 35.1% of patients had a POEM score ≤ 2 (AD clear/almost clear) compared with 0.1% at PSBL, and 49.9% had a DLQI score of 0 or 1 (no effect at all on patient’s life) compared with 1.5% at PSBL. At week 100, 74.5–97.3% of patients reported no effect of AD on the individual EQ-5D-3L domains, and 93.8% rated the effect of dupilumab treatment as “excellent,” “very good,” or “good” according to PGATE. Conclusion: In adults with moderate-to-severe AD, dupilumab treatment over 2 years resulted in sustained improvements in patient-reported symptoms and QoL and a favorable patient perception of treatment effect. Trial registration: ClinicalTrials.gov Identifier: NCT01949311. [MediaObject not available: see fulltext.].

Original languageEnglish (US)
Pages (from-to)2147-2157
Number of pages11
JournalDermatology and Therapy
Issue number6
StatePublished - Dec 2021


  • Adult
  • Atopic dermatitis
  • Clinical trial
  • Dermatology Life Quality Index
  • Dupilumab
  • EQ-5D
  • Efficacy
  • Long term
  • Patient-oriented eczema measure
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis'. Together they form a unique fingerprint.

Cite this